Combined monitoring of IgG and IgA anti-Spike and anti-Receptor binding domain long term responses following BNT162b2 mRNA vaccination in Greek healthcare workers

Autor: Ioannis Sarrigeorgiou, Dimitra Moschandreou, Alexios Dimitriadis, Gerasimina Tsinti, Evangelia Sotiropoulou, Eleni Ntoukaki, Petros Eliadis, Marija Backovic, Stavroula Labropoulou, Nicolas Escriou, Abraham Pouliakis, Georgia Giannopoulou, Eleni Gaitanarou, Konstantinos Lazaridis, Andreas Mentis, Avgi Mamalaki, Elisavet Grouzi, Peggy Lymberi
Přispěvatelé: Institut Pasteur Hellénique, Réseau International des Instituts Pasteur (RIIP), Saint Savvas Hospital, Virologie Structurale - Structural Virology, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d’innovation : vaccins – Innovation lab : vaccines, Institut Pasteur [Paris] (IP), Attikon University Hospital, We acknowledge support of this work by the HPI (Decision of the Administration Council, Reference Number: 14365 / 28.12.2020) and the project ‘INSPIRED’ (MIS 5002550), under the Action ‘Reinforcement of the Research and Innovation Infrastructure’, funded by the Operational Program ‘Competitiveness, Entrepreneurship and Innovation’ (NSRF 2014‐2020), action co-funded by the Greek Government and the European Union—European Regional Development Fund.
Rok vydání: 2022
Předmět:
Zdroj: PLoS ONE
PLoS ONE, 2022, 17 (11), pp.e0277827. ⟨10.1371/journal.pone.0277827⟩
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0277827⟩
Popis: International audience; Studies on the humoral response to homologous BNT162b2 mRNA-vaccination focus mainly on IgG antibody dynamics, while long-term IgA kinetics are understudied. Herein, kinetics of IgG and IgA levels against trimeric-Spike (S) and Receptor-Binding-Domain (RBD) were evaluated by in-house ELISAs in 146 two-dose vaccinated Greek healthcare workers (HCWs) in a 9-month period at six time points (up to 270 days after the first dose). The effect of a homologous booster third dose was also studied and evaluated. The peak of immune response was observed 21 days after the second dose; 100% seroconversion rate for anti-S and anti-RBD IgG, and 99.7% and 96.3% respectively for IgA. IgG antibody levels displayed higher increase compared to IgA. Declining but persistent anti-SARS-CoV-2 antibody levels were detected 9 months after vaccination; IgG and IgA anti-S levels approached those after the first dose, while a more rapid reduction rate for anti-RBD antibodies led to significantly lower levels for both classes, supporting the need for a booster dose. Indeed, a homologous booster third dose resulted in enhanced levels of anti-S of both classes, whereas anti-RBD didn’t exceed the peak levels after the second dose. Previous SARS-CoV-2 infection, flu vaccination, BMI
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje